The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The company has already told us they are fully funded until
“At least” June 2023
When will the money run out is being answered by the talks about JV with partners to move this drug forward
Agreed Costs. And whilst appreciating the range of questions investors need to raise tomorrow, the analysts will focus on one critical theme. When will your cash run out and how do you continue as a business without a further cash raise at a massively diluted price
This is the problem, Synairgen are no longer in control of their own destiny as now awaiting 'favours' from US and platform trials.
Another huge problem is Synairgen have been in control of their own destiny for the last 17+ years and look at the lack of progress made.
Valor.
You can lead a horse to water but you can't make it drink.
How many prescribed courses of antibiotics or antimalarials are not completed?
I don't see it as more sinister than that, disappointing as perhaps greater oversight by the trial nurses couldve kept more of the ~600 on the wagon.
Ridiculous that we haven't received A2 data, the longer we wait the more emphasis put on it and it's very unlikely to be the panacea.
Doc83
You are right..."So' many questions from Pi's as we have been starved of any
communication since the SPRINTER reasults..
I really hope RM respects the effort made by PI's to attend the AGM and gives
the time to address the issues they want to raise....ATB!
Thanks for all your efforts
There’s so many questions I could ask Synairgen, but I really want to know their thoughts on:
Polygon - we all seems fixated on them and their buying up of SNG shares, and rightly so. Heading up towards 30%, they are now extremely relevant to SNG’s future, so what are the board’s thoughts?
JV/Partnership - mentioned previously by RM, is this realistic? And if so, are we not in a perilously weak negotiating position, because any potential partner could threaten and say to us to go it alone ourselves, knowing we cannot afford this?
Recent hires - we hired a lot of expensive people when looking to scale up production on the back of a successful P3. This didn’t happen, so what are the plans for these people?
Clearly SNG do not have the ACTIV-2 results...Have they lodged a complaint?
Because it is simply obvious that it does not take this long......
Doubt RM would criticise the process as we want P3 to go ahead..
But frankly I think we are not being treated with respect!!
OK thanks Tommy ref SOC.
Maybe there is also detail of why a number 1 trial administrator would give poor dosage frequency and timing but if not great if the question can be asked.
I'm not saying administrators were involved in back handers (although I've witnessed it so many times) but if never explained previously, then we can ask the question without insinuating any foul play.
Maybe wrong dosage and good midway trial data that I had read in posts were just speculation rather than fact?
Anyway, good luck AGM'ers ??
Please read the Sprinter protocol. It DOES not say patients will only get sng001
It clearly states plus standard of care
“I remember reading posts saying that incorrect amount of doses were given eg. not the correct number per day, or not starting on day 1 etc. If true, then why no compensation from the trial administrators…”
Thanks Doc for your response. The reason I think that this is one of the most important questions is that a new platform trial will take time and might again involve steroid disadvantages and also in the meantime we could be bought out at a seriously reduced price).
My previous post is not saying that trial violations did happen intentionally but from many years experience, I know businessmen do whatever necessary to increase personal gain at the expense of all the decent genuine people and then the impartial nice people daren't whistleblow or create conflict.
I can accept a crash in savings and not saving 1000s of lives if a legitimate trial but couldn't live with never knowing if corruption has had its part (as said, I know for a fact it happens all the time so not a bazaar question to ask). Nice SNG scientists might not want to push the question but might be obliged to if a shareholders' AGM question.
So why dosage violations from the best trial administrators? Why SOC when patients sign to accept SNG dosage only? (that's why we did our own £70M trial).
Compensation and/or a retrial will give us a quick chance of justice and even a straight EUA, whereas further Platform delays gives the competition a chance to catch up or buy us out.
Wigster, Tommy great if it is question number 1 rather than live the rest of our lives not knowing what happened.
The Stacey Adams presentation is important. Where is the information?
Fair point Mr Costs :-)
Looks like Stacey Adams 15 minute slot was either cancelled or just a complete non event. No mention on Twitter or LinkedIn about anything related to her presentation.
Wigster - Have we missed the boat on potential huge orders? We can't even get a single order for this 'world beating all singing all dancing drug'.
You're welcome all.
Another question from me:
Prior to P3 results, brokers like Finncap and Numis were talking wildly high bull-figures of £75, £85 per share due to the expected desire of governments to stockpile drugs ready for future waves/viruses. During Synairgen's discussions with various trial organisers, regulatory bodies etc does this desire still appear to be there or has the fact that Covid has regressed (certainly for the minute) and other priorities like Russia/Ukraine etc mean that governments are now focussed elsewhere? (i.e. have we missed the boat on potential huge orders).
Thanks Wigster77
Superbly done, Wigster77.
I've collated some of the AGM Questions. In no particular order (post 2 of 2):
11 - Doc83/Manifesto - What is happening with the big name hires (presumably on significant salaries) brought in for commercialisation, since this is now on the back burner?
12 - Goblesmyth - As the company are in a state of limbo ref the Covid trials, has work been restarted with regards to COPD?
13 - HelloSanDiego - Has NIAID told you they're planning, or expect to plan, another trial to replace the cancelled ACTIV-2 P3 trial? If so, when is its targeted commencement date?
14 - HelloSanDiego - Are you in talks with any groups planning platform trials that are expected to commence dosing before spring next year?"
15 - HelloSanDiego - How many doses of SNG001 does the company currently have, and when do they expire?
16 - Investowin - How do you intend to ensure the survival of the business as a going concern when none of the actions currently targeted by the BOD generate revenues before your cash runs out?
17 - Manifesto - In 2020 RM and the Board awarded themselves 100% of their Salary as a bonus. Will they now repay it in full in light of their shareholders huge financial losses caused by the flaws in the design of SPRINTER? (£1.75 Placing funds used!!)
18 - Manifesto - Do they accept that the design of the SPRINTER trial failed and not the Drug?
19 - Manifesto - Is Emergency Use Authorisation a pathway the company would consider or not?
20 - Manifesto - How will the solid evidence that the drug works be achieved for commercialisation? Is the company still wanting to go down the road platform trial route as mentioned following P3 results? If so, realistic time scales?
21 - Wigster77 - SP down 90% - what would you say has been the biggest lesson learnt for Synairgen in the last year or so?
I've collated some of the AGM Questions. In no particular order (post 1 of 2):
1 - Blue83 - What is the most promising use for their treatment? COPD?
2 - Blue83 - Did they suspect that the performance of SNG001 would be undermined by treatments currently offered in Standard of Care?
3 - Blue83 - Are there situations or conditions where the current treatments offered as Standard of Care for Covid are inappropriate?
4 - Blue83 - Do they understand the causal mechanism for the ineffectiveness of their treatment, & if so, why did they go ahead with Sprinter?
5 - Doc83 - The new timeframe of “Summer” for ACTIV-2 P2 data: is this a guess, or have they been given actual guidance by the NIH? Was the previous H1 guideline a guess or were the goalposts moved?
6 - Doc83 - Given that we had already missed the peak of Covid, should we have not been quite so aggressive with our hires and commercialisation strategy, and waited until P3 results?
7 - Doc83 - Do you acknowledge how lacking communication was following the P3 results announcement and the biggest fall in SP in the company's history?
8 - Doc83 - Any plans to reveal any long Covid data?
9 - Doc83 - Do Synairgen and Polygon have a dialogue/talk to each other? If so, what about? If not, why not when they are so significant?
10 - Doc83 - Are Synairgen happy or have concerns there is such a large shareholder that could potentially influence the future direction of the company?
“I remember reading posts saying that incorrect amount of doses were given eg. not the correct number per day, or not starting on day 1 etc. If true, then why no compensation from the trial administrators…”
Fantastic question. 10’s of £millions spent on a trial for a third party(s) to mess it up. Compensation sounds fair to me.
Tommy
Don't know if already covered (AND whether it was fact or assumption when was posted months ago) but a question I would want passing on would be regarding the trial violations. I remember reading posts saying that incorrect amount of doses were given eg. not the correct number per day, or not starting on day 1 etc. If true, then why no compensation from the trial administrators to do a re-trial (or then give the compensation to a genuine administrator like Martin Landray of The Recovery Trial to do a trial). It's acceptable for trial failure due to the product etc but not if Big Pharma had threatened administrators to mess trials up or risk losing Big Pharma future business. I thought the trial had gone well midway through but not in the 2nd half?
So not sure if it is a valid question as I don't know the reasons/ outcome of the violations but if a possibility that it happened, then I think we should ask why the incompetent administration along with SOC etc. and encourage progression (as SNG seem to be genuine scientists rather than savvy businessmen, politicians, lawyers etc)
If so, then please reword the question as you or others will have more knowledge about the background.
Thanks
I’ve passed the question to those attending. I can’t guarantee they’ll be asked as the exact format for questions at the AGM is unknown. But the questions will also be passed on in written form. Any responses will be fed back.
Thanks to everyone who responded
HelloSanDiago
I’m a disappointed shareholder who believed in the product but acknowledge that this was a risky investment. RM and Synairgen never promised anything and underplayed the product if anything, data is King was the mantra.
I may however turn into a disgruntled investor on Thursday after the AGM if more detail is not provided on the trial and some clarity provided on plans for the future. I don’t want it to be a witch hunt but would like some honest feedback. As shareholders I think this is the least we expect and deserve.
ATB
SBT
It will be interesting to guage what these characters are like in real life.
Activ-2 and Poly are critical.
The main action indicated by RM in his interview was “Looking to partners to assist with moving the drug forward” that action surely is how they stop the money running out?
That